Patents Examined by Patricia Duffy
  • Patent number: 10285923
    Abstract: Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently (i) linked to the node structure by a linking group, or (ii) constituting a portion of one of the one or more cationic groups, wherein the composition has an average degree of polymerization determined by hydroxyl value testing (DPOH) of from about 3 to about 20. Also provided are polyglyceryl compounds which may compose such compositions, and uses of the polyglyceryl compositions and compounds.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: May 14, 2019
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Michael J. Fevola, Frank C. Sun, Stacey E. York
  • Patent number: 10258682
    Abstract: The invention provides vectors, attenuated pathogens, compositions, methods, and kits for use in preventing or treating infection by an infectious pathogen, especially Chlamydia trachomatis. The vectors comprise the plasmid encoded ppg genes from Chlamydia, ppg1, ppg2, ppg3, ppg5, ppg6, ppg7 and/or ppg8, but lack ppg4, a regulator of virulence associated genes. The application also provides attenuated pathogens, especially chlamydia, which are cured of their plasmid and have additional mutations to improve the attenuation, especially mutations in the CT135 gene or in the tryptophan operon (trp promoter, trpA, or trpB). Uses of said nucleic acids and attenuated pathogens for inducing or modulating an immune response in a subject, especially for prevention or treatment of infections, are proposed.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: April 16, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventor: Harlan D. Caldwell
  • Patent number: 10258681
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: April 16, 2019
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Patent number: 10226521
    Abstract: Recombinant attenuated Y. pseudotuberculosis mutants have been created that show efficacy as oral vaccines against plague caused by Y. pestis and Yersinosis caused by both Y. enterocolitica and Y. pseudotuberculosis. Thus, live attenuated Y. pseudotuberculosis-based vaccines can be used to prevent Yersinosis in farm animals such as swine, cattle and sheep. The palatable baits containing live attenuated Y. pseudotuberculosis-based vaccines may be acceptable methods to control plague epidemics in wild animals. The methods disclosed can also be used to generate recombinant attenuated Y. entercolitica and Y. pestis vaccine strains.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: March 12, 2019
    Assignee: Arizona Board of Regents on Behalf of Arizona State University
    Inventors: Roy Curtiss, Wei Sun
  • Patent number: 10226520
    Abstract: Certain embodiments are directed to compositions comprising EHEC-specific antigens. In certain aspects EHEC O157:H7-specific antigen(s) are used as components of immunogenic compositions and vaccines.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: March 12, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXA SYSTEM
    Inventor: Alfredo G. Torres
  • Patent number: 10215754
    Abstract: The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: February 26, 2019
    Assignee: Abbott Laboratories
    Inventors: Susan E. Brophy, David J. Hawksworth, Dinesh O. Shah, Robert W. Siegel, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann
  • Patent number: 10202606
    Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: February 12, 2019
    Assignees: NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ken Ishii, Kouji Kobiyama, Taiki Aoshi, Fumihiko Takeshita, Yuji Kasuya, Takako Niwa, Makoto Koizumi
  • Patent number: 10167124
    Abstract: A shaving cream formulation having one or more surfactants, one or more emulsifying agents, and water, wherein water is present in an amount of less than twenty weight percent based on total weight of the formulation. The shave cream formulation being compatible for use with a water-soluble film enclosure.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: January 1, 2019
    Assignee: PACIFIC SHAVING COMPANY
    Inventors: Stanley D. Ades, Cynthia C. Sofronas
  • Patent number: 10166194
    Abstract: The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: January 1, 2019
    Assignee: Diurnal Limited
    Inventors: Hiep Huatan, Richard Ross, Martin Whitaker
  • Patent number: 10155821
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: December 18, 2018
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
  • Patent number: 10149850
    Abstract: A composition for human consumption includes a base composition having a pH of about 2 to about 5 and encapsulated caffeine dispersed throughout at least a portion of the base composition. The encapsulated caffeine can be a caffeine complex. The base composition can include a liquid or a food. An oral pouch product includes a porous pouch wrapper, an inner botanical filling material contained within the pouch wrapper, and encapsulated caffeine dispersed throughout at least a portion of the oral pouch product. The encapsulated caffeine is included in the composition and/or the oral pouch product an amount sufficient to release about 50 mg to about 200 mg of caffeine. The composition can provide immediate release of caffeine and/or release of caffeine over an extended period of time.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: December 11, 2018
    Assignee: Altria Client Services LLC
    Inventors: Munmaya K. Mishra, Gerd Kobal
  • Patent number: 10144735
    Abstract: The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: December 4, 2018
    Assignee: 3M Innovative Properties Company
    Inventors: Doris Stoermer, George W. Griesgraber, Tushar A. Kshirsagar
  • Patent number: 10118972
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: November 6, 2018
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
  • Patent number: 10112999
    Abstract: Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: October 30, 2018
    Assignee: AbbVie Inc.
    Inventors: Edward B. Reilly, Mark Anderson
  • Patent number: 10098899
    Abstract: The invention relates to medicine, and specifically to synthetic biologically active derivatives of carbopentoxysulfanilic acid. The novel substance comprises a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula: Where X is Na, K, NH4; the drug may be contained in tablets, including sublingual tablets, or in capsules, or in suppositories, or in drops, or in mixtures, or in ointments, creams or other forms for application to the skin and mucosae, or in an oral-buccal film, or in a spray, or in a liquid for parenteral administration, or in chewing gum. A preparation having pronounced activity against herpes viruses is thus produced.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: October 16, 2018
    Inventors: Viktor Veniaminovich Tets, Georgy Viktorovich Tets
  • Patent number: 10072027
    Abstract: What is described is a process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration. The process is carried out using specifically controlled crystallization conditions. The more recent developments in the field of the gadolinium-containing MR contrast agents (EP 0448191 B1, CA Patent 1341176, EP 0643705 B1, EP 0986548 B1, EP 0596586 B1) include the MRT contrast agent gadobutrol (Gadovist® 1.0) which has been approved for a relatively long time in Europe and more recently also in the USA under the name Gadavist®.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: September 11, 2018
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Johannes Platzek, Wilhelm Trentmann
  • Patent number: 10058600
    Abstract: Detoxified variants of the pathogenic E. coli ‘AcfD precursor’ (orf3526) have been identified that raise a substantially similar immune response in a subject as the native AcfD (orB526) protein. The detoxified variants may be further modified to have increased solubility as compared to the native AcfD (orf3526) protein.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: August 28, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Laura Serino, Maria Rita Fontana, Danilo Gomes Moriel
  • Patent number: 10059750
    Abstract: The present application relates to compositions of modified toxins exhibiting cytotoxicity and/or reduced immunogenicity. Also provided are polypeptide toxophores from a modified diphtheria toxin, where modifications are in at least one amino acid residue of at least one T-cell epitope. Another aspect relates to a fusion protein which comprises a modified diphtheria toxin and a non-diphtheria toxin fragment that is a cell binding portion. Another aspect relates to the use of a modified diphtheria toxin for the treatment of a malignant disease or a non-malignant disease. A modified diphtheria toxin or fusion protein may be administered with one or more other agents.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 28, 2018
    Assignee: ANGELICA THERAPEUTICS, INC.
    Inventors: Claude Geoffrey Davis, Deepshikha Datta, Matthew Paul Baker, Alyson Jane Rust, Simon Keen
  • Patent number: 10029013
    Abstract: A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or More other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: July 24, 2018
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
  • Patent number: 10017771
    Abstract: Some HBL and NHE enterotoxins are known to cause food-borne diseases in humans. Enterotoxin-deficient mutants of member strains of the Bacillus cereus group that do not produce HBL, HBLa1, HBLa2, or NHE enterotoxins are disclosed. Enterotoxin-deficient mutants are suitable for use as biocontrol agents. Methods for making the mutants and for using the mutants are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: July 10, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jo Emily Handelsman, Amy Klimowicz, Changhui Guan